Clinical trial
Study to Evaluate the Safety and Tolerability of EP0042
NCT04581512 · Ellipses Pharma, Industry · Recruiting
Key facts
| NCT number | NCT04581512 |
|---|---|
| Title | Study to Evaluate the Safety and Tolerability of EP0042 |
| Official title | A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies |
| Lead sponsor | Ellipses Pharma, Industry |
| Status | Recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | EP0042, Venetoclax, Azacitidine (AZA) |
| Enrollment | 70 |
| Start date | Nov 2, 2020 |
| Primary completion | Oct 1, 2025 |
| Completion | Dec 1, 2026 |
| First posted | Oct 9, 2020 |
| Last update posted | Oct 14, 2025 |
| Countries | Australia, Netherlands, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: